Device Trial Radar · NCT05483985
Evaluation of the Alife Hera System as an Adjunctive Tool for the Prioritization of Embryos Deemed Suitable for Transfer
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
444
Actual
Start
Jul 11, 2022
Primary completion
Sep 19, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Alife HealthNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years, up to 43 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the clinical pregnancy rate (pregnancy defined as fetal heartbeat at 6-8 weeks) with the adjunctive use of the Hera System (Hera System used with traditional morphological grading) with embryos already deemed suitable for transfer compared to trained embryologists using standard morphology criteria alone.
Conditions
- Infertility
Interventions
Hera ScoreDevice
The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: up to 8 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
CCRM
Menlo Park, California
Reproductive Science Center
San Ramon, California
IVF Florida Reproductive Associates
Margate, Florida
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.